As the latter is postulated to augment the negative side effects in highly proliferative, non-tumor tissues associated with PLK1-specific inhibitors (45–47), it will be of interest to see if BAL0891s unique kinase inhibition profile and potential for intermittent dosing will lead to a favorable therapeutic index in cancer patients. The gene discussed is PLK1; the disease is cancer.